Human Gene Therapy Division of the Department of Medical Genetics, Akdeniz University Faculty of Medicine, Antalya, Turkey.
Head Neck. 2011 Sep;33(9):1278-84. doi: 10.1002/hed.21598. Epub 2010 Nov 10.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC).
Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry.
An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN).
TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC.
肿瘤坏死因子（TNF）相关凋亡诱导配体（TRAIL）是一种正在进行临床试验的用于癌症治疗的死亡配体。然而，对于喉鳞状细胞癌（SCC）或口腔鳞状细胞癌（OCSCC）患者，其 TRAIL 和 TRAIL 受体的分子谱尚未确定。
对 60 例喉 SCC 患者和 14 例 OCSCC 患者的石蜡包埋组织进行回顾性免疫组织化学分析。
与良性病变对照者相比，喉 SCC 患者和 OCSCC 患者的诱饵受体 1（DcR1）表达增加，而诱饵受体 2（DcR2）表达减少。临床和病理分级显示，头颈部鳞状细胞癌（SCCHN）患者的 TRAIL 和 TRAIL 受体表达谱存在明显差异。
TRAIL 和 TRAIL 受体表达谱可能有助于通过与喉 SCC 患者的临床分期和病理分级相关联来监测疾病进展。
